Company
AboutTeamImpact
Science
Development ModelFocus AreasPipeline
Partnering
Business ModelPartners
Proof
Case StudiesContact
Home / Partners

Partner with us.

A clear process for licensing, co-development and co-investment, and answers to the questions partners ask first.

Partnering Process

What happens after you reach out.

A structured path from first contact to a signed agreement.

01

Initial Evaluation

We review fit against your therapeutic focus, regulatory footprint, and commercial goals.

02

Mutual NDA

A confidentiality agreement is executed before any program-level detail is shared.

03

Data Room Access

Qualified partners receive target product profiles, regulatory pathway, and development timelines.

04

Diligence

Joint technical and commercial review of the specific program(s) of interest.

05

Term Sheet

Licensing, co-development, or technology transfer terms are structured and agreed.

Frequently Asked

What partners ask us first.

Straight answers to the questions that usually come up early — with anything competitively sensitive reserved for the NDA'd conversation.

What stage is your pipeline at?
We share pipeline composition and maturity in aggregate — see the Pipeline section above for our current stage distribution by dosage form. Program-level stage detail is reserved for qualified partners under NDA.
What is your IP position?
4 patents filed to date, spanning our complex injectable and advanced-delivery development programs.
Which markets are you targeting for commercialisation?
In order of priority: the United States, the EU (EMA) and UK, Canada, and Latin America.
How large is your team?
50+ people globally, spanning R&D, regulatory, IP, and commercial functions across our UK and India operations.
How capital-efficient is your model?
Financial and capital efficiency detail is reserved for qualified partners and investors under NDA.
What's your competitive edge?
Beyond our dual-hub model and formulation depth: real agility and discipline as a focused organisation, and a willingness to own and fund development risk ourselves. By the time a program reaches a partner, much of the de-risking has already happened at our expense, not theirs.
Do you offer co-development and co-investment on products?
Yes. Our portfolio includes both models: programs we self-fund through to a de-risked, licensable state, and programs structured as collaborations from an earlier stage, where co-investment and risk-sharing are explored jointly with the partner.
Are you open to other markets?
Yes — while our current priority markets are the US, EU/UK, Canada, and Latin America, we're open to discussing other geographies where there's a clear fit with a partner's footprint or a program's commercial opportunity.
Next step

Discuss a program, licence or collaboration.